The Fund Grade · free · no account needed
What grade does HRCVX get?
Morningstar rates funds on what they returned. We grade them on where their money sits today: how much of the book overlaps with the converged buys of the top specialist stock pickers.
Fundprints Fund Grade · as of 2026-09-01
Carillon Eagle Growth & Income Fund Class A
#108 of 440 graded active funds · growth · large segment peer group
The point · specialist footprint
HRCVX puts more of its book behind proven specialists than 82% of graded funds.
Bottom 20%
Bottom 40%
Middle
Top 40%
● Top 20%
That has mattered: over the past 2.7 years, funds on this rung beat bottom-rung funds by about 3.8 points per quarter, and beat the S&P in 43% of fund-quarters versus their 22%. The evidence argues this fund earns its seat.
2,825 graded funds · 2.7 years of filings, measured as they were published · evidence, not advice
The grade scores this fund's specialist share — the slice that overlaps what the top 1% of proven funds are building. We ignore index ballast and names outside our edge on purpose: that slice is small, and it's what decides the outcome.
Conviction exposure
35.3%
of the book in specialist-converged names
Late-stage weight
20.1%
of the book in Crowded or Fading names
Active share
87.2%
how far it strays from the index
The best grades have beaten the worst by about +5% a year since we began grading. The gap held in 9 out of 10 months. Measured on filings as they were published, no hindsight.
Inside the book — top names by stage · as of 2026-09-09
We email you the day it crosses 50% crowded, and where you stand every month.
Graded monthly from point-in-time filings. A description of where the money sits, not a recommendation. Evidence, not advice.
The read · what to do with it
Carillon Eagle Growth and Income earns a B grade and ranks 108 of 440 graded funds, with specialists holding 35% of the book. The early story centers on MCD, ABT, and ICE, but AVGO, PG, and TJX are all flagged Fading, meaning those three positions together carry real exit risk.
→ Watch AVGO, PG, and TJX closely as specialists are actively leaving all three, which together represent roughly 10% of the fund.
→ Note that MCD, ABT, and ICE are Emerging stage positions where the fund appears genuinely early relative to broader ownership.
Support leaving these positions
Read from today's disclosed book. Evidence, not advice.
The evidence base updates this week.
The specialists — not the whales — are already positioned for what comes next. Stop finding out last.
Create your free accountNo card required · open the feed in 30 seconds